Clinical Trials

Phase 3 Active not recruiting

40 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Phase 1 Terminated

122 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04940052 2025-12-02

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

153 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

DermatologicEndocrineHead & NeckThoracic

Melanoma, Skin Neoplasms

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1 Suspended

71 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

209 enrolled

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03551626 2025-04-29

COMBI-APlus

552 enrolled 12 charts

Fever, Melanoma

NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

151 enrolled 45 charts 1 FDA

CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

NCT01682083 2023-08-30

COMBI-AD

870 enrolled 13 charts 1 FDA

Melanoma, Neoplasms

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02130466 2022-08-01

MK-3475-022

Phase 1/2 Completed

184 enrolled 62 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

177 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT01677741 2021-11-24

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Phase 1/2 Completed

85 enrolled 25 charts

CNS

Brain Neoplasms

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

31 enrolled

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

423 enrolled 15 charts

Melanoma

NCT03391050 2019-07-31

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Phase 1/2 Terminated

3 enrolled

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

430 enrolled 61 charts

Melanoma, Neoplasms

NCT02039947 2019-05-21

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

127 enrolled 17 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

68 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

NCT01231594 2019-03-22

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

214 enrolled

Neoplasms

NCT02314143 2019-02-18

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Phase 2 Terminated

48 enrolled 20 charts

Melanoma, Neoplasms

NCT02447939 2018-09-14

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Phase 1 Withdrawn

Melanoma

NCT01978236 2018-08-17

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Phase 2 Terminated

6 enrolled 9 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02672358 2018-08-10

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01767454 2017-11-14

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

38 enrolled

Melanoma

NCT00880321 2017-11-13

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

170 enrolled

Neoplasms

NCT01262963 2017-11-13

An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors

4 enrolled

Neoplasms

NCT01340833 2017-11-13

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

6 enrolled

Neoplasms

NCT01340846 2017-11-13

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

48 enrolled

Neoplasms

NCT01582997 2017-11-13

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

12 enrolled

Neoplasms

NCT01738451 2017-11-13

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

50 enrolled

Neoplasms

NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

251 enrolled 21 charts

Melanoma, Neoplasms

NCT01153763 2017-09-27

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

92 enrolled 22 charts

Melanoma

NCT01928940 2017-07-24

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

12 enrolled 28 charts

Melanoma

NCT02082665 2017-07-24

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

6 enrolled